MRI Radiomics to Predict Early Treatment Response to TACE Combined with Lenvatinib Plus a PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Purpose: To develop and validate a predictor for early treatment response in hepatocellular carcinoma (HCC) patients accompanied by portal vein tumor thrombus (PVTT) undergoing transarterial chemoembolization (TACE), lenvatinib and a programmed cell death protein 1 (PD-1) inhibitor (TLP) therapy. Patients and Methods: In this retrospective study, patients with HCC and PVTT from two institutions receiving triple TLP therapy were enrolled. Radiomics features derived from pretreatment contrast-enhanced MRI were curated using intraclass correlation coefficient (ICC), Student's Results: Our study ultimately included 115 patients (7:3 randomization, 80 and 35 in the training and test cohorts, respectively) in total. No patients achieved complete remission, 47 achieved partial remission, 29 achieved stable disease, and 39 experienced disease progression. Among objective response rates (ORRs) and disease control rates (DCRs), 40.9% and 66.1% were reported. One of the four ML classifiers with optimal performance, namely random forest, was adopted as the radiomics model after testing. Regarding the performance assessment, the radiomics model's area under the curve (AUC) values reached 0.92 (95% CI: 0.86-0.97) and 0.79 (95% CI: 0.61-0.95), inferior to the combined model's AUCs of 0.95 (95% CI: 0.68-0.98) and 0.84 (95% CI: 0.91-0.99). Moreover, the SHAP plots illustrate the importance of global variables and the prediction process for individual samples. Conclusion: The model based on machine learning and radiomics showed favorable performance, and the operating mode was visualized through SHAP.